Strong Financial Performance: Argenx reported a total operating income of $967 million for Q2 FY 2025, reflecting a 97% year-over-year growth driven largely by product net sales of $949 million. The growth is attributed to the exceptional demand for VYVGART, as the company treats over 15,000 patients globally, including 2,500 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) just one year post-launch.

Diversification of VYVGART Usage: The company successfully launched the prefilled syringe (PFS) format of VYVGART, which accounted for 50% of new patients starting treatment, driving physician and patient engagement. Over 1,000 physicians have written PFS prescriptions, expanding the prescriber base and unlocking new patient segments. The expectation is to reach 50,000 patients by 2030, indicating long-term market potential.

Pipeline Development and Expansion: Argenx has multiple registrational trials ongoing for VYVGART in additional indications such as myositis, Sj?gren's, and other autoimmune diseases. The company is also introducing two Phase III studies for empasiprubart against IVIg, showcasing a strategic focus on expanding its product portfolio and market presence in competitive environments.